logo

For the Inventor, By the Inventor

Planegg, Germany

4Sc Ag


USPTO Granted Patents = 52

% Expired Patents = 53.8



Trademarks = 3

Forward Citations = 382

Loading Chart...
Loading Chart...

76 inventors (with patents filed for the assignee):

goldMedal Thomas Beckers (19 out of 36 patents)

silverMedal Thomas Maier (17 out of 45 patents)

bronzeMedal Johann Leban (12 out of 17 patents)

4.  Thomas Baer (10 out of 13 patents)

5.  Petra Gimmnich (9 out of 9 patents)

6.  Mathias Schmidt (9 out of 9 patents)

7.  Stefan Tasler (8 out of 11 patents)

8.  Volker Gekeler (8 out of 12 patents)

9.  Thomas Bär (8 out of 11 patents)

10.  Astrid Zimmermann (8 out of 15 patents)

11.  Klaus Pekari (8 out of 8 patents)

12.  Matthias Vennemann (7 out of 11 patents)

13.  Stefano Pegoraro (6 out of 6 patents)

14.  Daniel Vitt (5 out of 14 patents)

15.  Kristina Wolf (5 out of 5 patents)


Core Competencies:
HDAC Inhibitors
Kv1.3 Inhibitors
Cancer Therapy
Sulfonylpyrroles
Indolopyridines
Tetrahydropyridothiophenes
Anti-inflammatory Agents
Immunomodulatory Compounds
Proliferative Diseases
Virostatic Compounds
Phenanthridine Analogues
Heterocyclic Inhibitors

52 patents:

1. 12285410 - Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy (2025-04-29),
2. 10822345 - KV1.3 inhibitors and their medical application (2020-11-03),
3. 10723743 - Kv1.3 inhibitors and their medical application (2020-07-28),
4. 10633369 - Method of inhibiting DYRK1B (2020-04-28),
5. 10399991 - Kv1.3 inhibitors and their medical applications (2019-09-03),
6. 10005769 - 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors (2018-06-26),
7. 9951050 - Method of inhibiting DYRK1B (2018-04-24),
8. 9908880 - Substituted imidazoquinolines (2018-03-06),
9. 9446040 - Substituted imidazoquinolines (2016-09-20),
10. 9073913 - Substituted imidazoquinolines (2015-07-07),
11. 8969401 - Sulfonylpyrroles (2015-03-03),
12. 8815855 - N-sulphonylpyrroles and their use as histone deacetylase inhibitors (2014-08-26),
13. 8785659 - Method for the production of sulphonylpyrroles as HDAC inhibitors (2014-07-22),
14. 8575193 - N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds (2013-11-05),
15. 8557991 - Process for preparing enantiomerically pure indolopyridines (2013-10-15),
Company Overview
4SC AG is a biotechnology company based in Planegg, Germany, specializing in the development of innovative cancer therapeutics. The company focuses on advancing treatments through its expertise in various core technologies, including HDAC inhibitors and Kv1.3 inhibitors. 4SC's research encompasses a range of compounds such as sulfonylpyrroles, indolopyridines, and tetrahydropyridothiophenes, aimed at addressing cancer and inflammatory diseases. The organization is committed to enhancing patient outcomes through its targeted therapeutic approaches.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

4Sc Ag USPTO Patent Assignee Logo
52 Patents

#2 in Planegg

#1,022 in Germany

#13,571 in the World

Planegg, DE
Planegg, Germany

4Sc Ag

Forward Citations = 382

76 inventors:

goldMedal Thomas Beckers (19 out of 36 patents)

silverMedal Thomas Maier (17 out of 45 patents)

bronzeMedal Johann Leban (12 out of 17 patents)

4.  Thomas Baer (10 out of 13 patents)

5.  Petra Gimmnich (9 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: 4Sc Ag. Retrieved from https://idiyas.com/company/4sc-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…